stockrow
Saturday 7 November 2026
Export OVID’s income statement to Excel — free account
Ovid Therapeutics
OVID Healthcare Biotechnology
Ovid Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $7.3 million, up 1,181.3% from fiscal 2024.
- Revenue
- +463.9%
- EPS
- −33.3%
- Free cash flow
- −268.5%
- Total debt
- −11.7%
Quarter to June 2026, against a year earlier
2.87
0.29
+11.24%
Follow OVID
Alert me
Ovid Therapeutics (OVID) P/E ratio
Ovid Therapeutics has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 3.0× (June 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 1.8× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.0×
Ten-year median
0.0×
Current reading's percentile
89
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | n/m |
| NGNE Neurogene Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| ENTX Entera Bio Ltd. compare | n/m |
| OVID Ovid Therapeutics | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 15.3× |
| YDES YD Bio Limited compare | — |
| SLBT SL SCIENCE HLDG compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)